NeoruscogeninCAS# 17676-33-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 17676-33-4 | SDF | Download SDF |
PubChem ID | 9910474 | Appearance | Powder |
Formula | C27H40O4 | M.Wt | 428.61 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Synonyms | 25(27)-Dehydroruscogenin | ||
Solubility | Soluble in ethanol and methanol; slightly soluble in water | ||
SMILES | CC1C2C(CC3C2(CCC4C3CC=C5C4(C(CC(C5)O)O)C)C)OC16CCC(=C)CO6 | ||
Standard InChIKey | ALTRINCJVPIQNK-NHIXJPGBSA-N | ||
Standard InChI | InChI=1S/C27H40O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,16,18-24,28-29H,1,6-14H2,2-4H3/t16-,18+,19+,20-,21-,22-,23+,24-,25-,26-,27+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Neoruscogenin represents a universal pharmacological tool for RORα research due to its specific selectivity profile versus other nuclear receptors. |
Neoruscogenin Dilution Calculator
Neoruscogenin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3331 mL | 11.6656 mL | 23.3312 mL | 46.6625 mL | 58.3281 mL |
5 mM | 0.4666 mL | 2.3331 mL | 4.6662 mL | 9.3325 mL | 11.6656 mL |
10 mM | 0.2333 mL | 1.1666 mL | 2.3331 mL | 4.6662 mL | 5.8328 mL |
50 mM | 0.0467 mL | 0.2333 mL | 0.4666 mL | 0.9332 mL | 1.1666 mL |
100 mM | 0.0233 mL | 0.1167 mL | 0.2333 mL | 0.4666 mL | 0.5833 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- trans-Hinokiresinol
Catalog No.:BCN1130
CAS No.:17676-24-3
- Phorbol
Catalog No.:BCN3726
CAS No.:17673-25-5
- KN-92
Catalog No.:BCC1680
CAS No.:176708-42-2
- Delphinidin-3,5-O-diglucoside chloride
Catalog No.:BCN1522
CAS No.:17670-06-3
- Ducheside A
Catalog No.:BCN1129
CAS No.:176665-78-4
- H-D-Leu-OBzl.TosOH
Catalog No.:BCC2976
CAS No.:17664-93-6
- Urocortin (human)
Catalog No.:BCC5788
CAS No.:176591-49-4
- AAL Toxin TE2
Catalog No.:BCN1742
CAS No.:176590-38-8
- AAL Toxin TE1
Catalog No.:BCN1737
CAS No.:176590-37-7
- AAL Toxin TD2
Catalog No.:BCN1740
CAS No.:176590-36-6
- AAL Toxin TD1
Catalog No.:BCN1735
CAS No.:176590-35-5
- AAL Toxin TC2
Catalog No.:BCN1741
CAS No.:176590-34-4
- Ageratochromene dimer
Catalog No.:BCN8110
CAS No.:17678-76-1
- (RS)-3,4-DCPG
Catalog No.:BCC7045
CAS No.:176796-64-8
- Homoplantaginin
Catalog No.:BCN2488
CAS No.:17680-84-1
- Metergoline
Catalog No.:BCC6709
CAS No.:17692-51-2
- CCT007093
Catalog No.:BCC5147
CAS No.:176957-55-4
- LY 320135
Catalog No.:BCC7346
CAS No.:176977-56-3
- 2alpha,19alpha-Dihydroxy-3-oxo-urs-12-en-28-oic acid
Catalog No.:BCN7406
CAS No.:176983-21-4
- Ambrisentan
Catalog No.:BCC4887
CAS No.:177036-94-1
- R 568 hydrochloride
Catalog No.:BCC7781
CAS No.:177172-49-5
- 26-O-Acetylsootepin A
Catalog No.:BCN7699
CAS No.:1772588-99-4
- Aglain B
Catalog No.:BCN6636
CAS No.:177262-32-7
- DBeQ
Catalog No.:BCC3916
CAS No.:177355-84-9
Spirostanol saponins and esculin from Rusci rhizoma reduce the thrombin-induced hyperpermeability of endothelial cells.[Pubmed:23499166]
Phytochemistry. 2013 Jun;90:106-13.
Rusci rhizoma extracts are traditionally used against chronic venous disorders (CVD). To determine the effect of its secondary plant metabolites on the endothelium, phenolic compounds and saponins from Butcher's broom were isolated from a methanolic extract, and their activity on the thrombin-induced hyperpermeability of human microvascular endothelial cells (HMEC-1) was investigated in vitro. In addition to the six known spirostanol saponins deglucoruscin (5), 22-O-methyl-deglucoruscoside (6), deglucoruscoside (7), ruscin (8), ruscogenin-1-O-(alpha-l-rhamnopyranosyl-(1-->2)-beta-d-galactopyranoside (9) and 1-O-sulpho-ruscogenin (10), three new spirostanol derivatives were isolated and identified: 3'-O-acetyl-4'-O-sulphodeglucoruscin (1), 4'-O-(2-hydroxy-3-methylpentanoyl)-deglucoruscin (2) and 4'-O-acetyl-deglucoruscin (3). Furthermore, the coumarin esculin (4), which is also prominently present in other medicinal plants used in the treatment of CVD, was isolated for the first time from Rusci rhizoma. Five of the isolated steroid derivatives (2, 5, 8, 9 and 10) and esculin (4) were tested for their ability to reduce the thrombin-induced hyperpermeability of endothelial cells in vitro, and the results were compared to those of the aglycone Neoruscogenin (11). The latter compound showed a slight but concentration-dependent reduction in hyperpermeability to 71.8% at 100muM. The highest activities were observed for the spirostanol saponins 5 and 8 and for esculin (4) at 10muM, and these compounds resulted in a reduction of the thrombin-induced hyperpermeability to 41.9%, 42.6% and 53.3%, respectively. For 2, 5 and 8, the highest concentration tested (100muM) resulted in a drastic increase of the thrombin effect. The effect of esculin observed at a concentration of 10muM was diminished at 100muM. These in vitro data provide insight into the pharmacological mechanism by which the genuine spirostanol saponins and esculin can contribute to the efficacy of Butcher's broom against chronic venous disorders.
The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORalpha (NR1F1).[Pubmed:23896689]
J Biomol Screen. 2014 Mar;19(3):399-406.
Plants represent a tremendous structural diversity of natural compounds that bind to many different human disease targets and are potentially useful as starting points for medicinal chemistry programs. This resource is, however, still underexploited due to technical difficulties with the identification of minute quantities of active ingredients in complex mixtures of structurally diverse compounds upon raw phytomass extraction. In this work, we describe the successful identification of a novel class of potent RAR-related orphan receptor alpha (RORalpha or nuclear receptor NR1F1) agonists from a library of 12,000 plant extract fractions by using an optimized, robust high-throughput cell-free screening method, as well as an innovative hit compound identification procedure through further extract deconvolution and subsequent structural elucidation of the active natural compound(s). In particular, we demonstrate that Neoruscogenin, a member of the steroidal sapogenin family, is a potent and high-affinity RORalpha agonist, as shown by its activity in RORalpha reporter assays and from its effect on RORalpha target gene expression in vitro and in vivo. Neoruscogenin represents a universal pharmacological tool for RORalpha research due to its specific selectivity profile versus other nuclear receptors, its excellent microsomal stability, good bioavailability, and significant peripheral exposure in mouse.